

Archamps (France), March 12th, 2018 at 5.45 pm CET

Genkyotex to Present Corporate Overview at 30th Annual ROTH Conference

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that it will participate in the 30th Annual ROTH Conference, taking place on March 11-14, 2018, at the Ritz Carlton Hotel in Laguna Niguel, California. The Company's Chief Executive Officer, Elias Papatheodorou, will present a corporate overview, and Philippe Wiesel, M.D., Genkyotex's Executive Vice President, and Chief Medical Officer, will participate in two fibrotic disease-related panels.

Next financial press release:

Q1 2018 business update and cash position: April 25th, 2018 (after market)

About Genkyotex

Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

Genkyotex's platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is evaluated in a phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) and in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD). This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, currently undergoing preclinical testing.

Genkyotex also has a versatile platform well-suited to the development of various immunotherapies (Vaxiclase). A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Ltd (Serum Institute), the world's largest producer of vaccine doses, for the development by Serum Institute of cellular multivalent combination vaccines against a variety of infectious diseases. This partnership could generate up to \$57 million in future revenues for Genkyotex, before royalties on sales.

For further information, please go to www.genkyotex.com.



Disclaimer

This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genkyotex shares in any country, in particular any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or other qualification under the securities laws of any such jurisdiction.

INVESTORS	MEDIA	US
NewCap Dušan Orešanský, Tristan Roquet Montégon and Emmanuel Huynh +33 1 44 71 94 92 genkyotex@newcap.eu	ALIZE RP Caroline Carmagnol +33 6 64 18 99 59 +33 1 44 54 36 65 genkyotex@alizerp.com	LifeSci Advisors, LLC Brian Ritchie +1-212-915-2578 britchie@lifesciadvisors.com